Routes of the same type are on the same row. Compare other markets.
19 pathway types exist in both markets: full application, new active substance, full or mixed application, known active substance, generic application, biosimilar application, well-established use, non-prescription application and more. The table lines up the routes of each type.
Germany: Centralised marketing authorisation, new active substance, 210 days. Netherlands: Centralised marketing authorisation, new active substance, 210 days. These are official targets, not actual review times.
| Pathway type | Germany | Netherlands |
|---|---|---|
| Full application, new active substance | National marketing authorisation (new active substance)§ 21 AMG · fee €52,500 Centralised marketing authorisation, new active substancetarget 210 days · fee €865,200 Centralised authorisation of advanced therapy medicinal productstarget 210 days · fee €865,200 National authorisation of vaccines, sera, blood products and allergens (Paul-Ehrlich-Institut)§§ 21, 25 Abs. 8, 77 Abs. 2 AMG · fee €2,000 | Centralised marketing authorisation, new active substancetarget 210 days · fee €865,200 |
Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.
| Full or mixed application, known active substance | Centralised marketing authorisation, known active substance or new fixed combinationtarget 210 days · fee €690,700 Centralised hybrid applicationtarget 210 days · fee €426,100 | Centralised marketing authorisation, known active substance or new fixed combinationtarget 210 days · fee €690,700 Centralised hybrid applicationtarget 210 days · fee €426,100 |
| Generic application | Centralised generic applicationtarget 210 days · fee €177,900 National generic authorisation§ 24b AMG · fee €16,000 | Centralised generic applicationtarget 210 days · fee €177,900 National generic or hybrid applicationfee €37,290 |
| Biosimilar application | Centralised biosimilar applicationtarget 210 days · fee €732,400 | Centralised biosimilar applicationtarget 210 days · fee €732,400 |
| Well-established use | National authorisation based on literature (well-established use)§ 22 Abs. 3 AMG · fee €22,100 Centralised well-established use applicationtarget 210 days · fee €780,900 | Centralised well-established use applicationtarget 210 days · fee €780,900 |
| Non-prescription application | Prescription status and switch to non-prescription§ 48 AMG; AMVV |
| Non-prescription monograph | Standard licence (monograph route)§ 36 AMG; StandZV | - |
| Traditional or herbal registration | Traditional herbal medicine registration§§ 39a to 39d AMG · fee €15,600 | Traditional herbal medicine registrationfee €5,670 |
| Conditional or accelerated approval | Conditional marketing authorisationtarget 210 days | Conditional marketing authorisationtarget 210 days |
| Approval under exceptional circumstances | Authorisation under exceptional circumstancestarget 210 days | Authorisation under exceptional circumstancestarget 210 days |
| Priority or accelerated review | Accelerated assessmenttarget 150 days | Accelerated assessmenttarget 150 days |
| Intensive development support designation |
| Orphan or rare disease designation | Orphan designationtarget 90 days | Orphan designationtarget 90 days |
| Pediatric plan or incentive | Paediatric investigation plantarget 60 days | Paediatric investigation plantarget 60 days |
| Early or compassionate access | Compassionate use programme§ 21 Abs. 2 Nr. 3 AMG; AMHV | Supply on physician statement (named patient)Gmw Art. 40(3)(c) |
| Reliance route, recognition or verification | Mutual recognition procedure (Germany as reference or concerned member state)§ 25b Abs. 2 AMG · fee €48,600 · relies on EU Mutual recognition proceduretarget 90 days | Mutual recognition and repeat use: Dutch steps and feesNL/H/xxxx/xxx/MR · fee €31,990 Licence for public health reasons (product marketed elsewhere in the EU)Gmw Art. 52 · relies on EU Mutual recognition proceduretarget 90 days |
| Work-sharing or joint review | Decentralised procedure with Germany as reference member state§ 25b Abs. 3 AMG · fee €92,800 Decentralised proceduretarget 210 days | Decentralised procedure: Dutch steps and feesNL/H/xxxx/xx/DC · fee €102,640 Decentralised proceduretarget 210 days |
| Device: exempt or self-declared |
| Device: conformity assessment by a certification body |
| Device: registration or licence with the regulator | - |
| Other route | Homeopathic medicine registration§§ 38, 39 AMG · fee €6,400 Official batch release by the Paul-Ehrlich-Institut§ 32 AMG · relies on EU Hospital exemption for advanced therapy medicines§ 4b AMG · fee €4,250 Approval of tissue preparations§ 21a AMG · fee €2,000 Special national authorisation for a device without CE marking§ 7 MPDG · fee €250 DiGA fast track: listing of digital health applications for reimbursement§ 139e SGB V; DiGAV · target 91 days · fee €3,000 Listing of digital care applications (DiPA)§ 78a SGB XI; DiPAV · target 91 days · fee €3,000 Integral drug-device combination authorised as a medicinetarget 210 days | Informed consent applicationArt. 10c Directive 2001/83/EC · fee €9,380 Duplex marketing authorisationfee €9,380 Homeopathic medicine registrationfee €3,890 Parallel import licenceRVG2//RVG1 · fee €2,600 Temporary import exemption during shortagesRegeling Gmw Art. 3.17a · relies on EU, GB Hospital exemption for advanced therapy medicinesGmw Art. 40(3)(d) |